Succinylacetone
Page Template:Chembox/styles.css has no content.
Template:Chembox IndexlistTemplate:Chembox CompToxTemplate:Chembox GHS (set)Template:Chembox Datapage check| Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found. | |
| Names | |
|---|---|
| Preferred IUPAC name
4,6-Dioxoheptanoic acid | |
| Other names
Succinyl acetone
| |
| Identifiers | |
| Page Template:Plainlist/styles.css has no content. | |
3D model (JSmol)
|
Page Template:Plainlist/styles.css has no content. |
| ChEBI | Page Template:Plainlist/styles.css has no content. |
| ChEMBL | Page Template:Plainlist/styles.css has no content. |
| ChemSpider | Page Template:Plainlist/styles.css has no content. |
| EC Number | Page Template:Plainlist/styles.css has no content. |
PubChem CID
|
Page Template:Plainlist/styles.css has no content. |
| RTECS number | Page Template:Plainlist/styles.css has no content. |
| UNII | Page Template:Plainlist/styles.css has no content. |
| |
| |
| Properties | |
| C7H10O4 | |
| Molar mass | 158.153 g·mol−1 |
| Hazards | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Template:Chembox Footer/trackingTemplate:Short description
Succinylacetone is a toxic organic compound that arises as an abnormal metabolite in tyrosine catabolism. In normal tyrosine catabolism, fumarylacetoacetate hydrolase converts fumarylacetoacetate to fumarate and acetoacetate. Deficiency of fumarylacetoacetate hydrolase leads to the accumulation of fumarylacetoacetate, which is subsequently converted to succinylacetoacetate. Succinylacetoacetate is then decarboxylated to form succinylacetone.
Patients with tyrosinemia type 1 have a congenital deficiency of fumarylacetoacetate hydrolase, resulting in the accumulation of succinylacetone in blood and urine. Elevated levels of succinylacetone, with or without elevations of tyrosine, are indicative of tyrosinemia type 1. Measurement of succinylacetone is the preferred marker in newborn screening of Tyrosinemia Type 1 due to its high sensitivity and specificity. [1] Succinylacetone can also be detected in the urine through LCMS or GCMS.
Succinylacetone also inhibits ALA dehydratase (PBG synthase), an enzyme involved in porphyrin and heme synthesis. This results in increased ALA levels and, in certain patients, precipitates acute neuropathic symptoms, similar to porphyria. Decreased heme concentration can also be seen as a result of this potent inhibition [2]
References
Page Template:Reflist/styles.css has no content.
- ^ Page Module:Citation/CS1/styles.css has no content.de Laet C, Dionisi-Vici C, Leonard JV, McKiernan P, Mitchell G, Monti L, et al. (January 2013). "Recommendations for the management of tyrosinaemia type 1". Orphanet Journal of Rare Diseases. 8 8. doi:10.1186/1750-1172-8-8. PMC 3558375. PMID 23311542.
- ^ Page Module:Citation/CS1/styles.css has no content.Ebert P, Hess R, Frykholm B, Tschudy D (1979). "Succinylacetone, a potent inhibitor of heme biosynthesis: effect on cell growth, heme content and δ-aminolevulinic acid dehydratase activity". Biochemical Pharmacology. 88: 1382–1390. doi:10.1016/0006-291X(79)91133-1.
